MESO SCALE DISCOVERY

MULTI-ARRAY® Assay System

Human Total Active GLP-1 Assay Kit

1-Plate Kit 5-Plate Kit 20-Plate Kit K151HZC-1 K151HZC-2 K151HZC-3

MESO SCALE DISCOVERY MESO SCALE DISCOVERY



MSD Metabolic Assays

Human Total Active GLP-1 Assay Kit

This package insert must be read in its entirety before using this product.

FOR RESEARCH USE ONLY.

NOT FOR USE IN DIAGNOSTIC PROCEDURES.

MESO SCALE DISCOVERY®

A division of Meso Scale Diagnostics, LLC. 9238 Gaither Road Gaithersburg, MD 20877 USA www.mesoscale.com

MESO SCALE DISCOVERY, MESO SCALE DIAGNOSTICS, WWW.MESOSCALE.COM, MSD, MSD (DESIGN), DISCOVERY WORKBENCH, QUICKPLEX, MULTI-ARRAY, MULTI-SPOT, SULFO-TAG, SECTOR, SECTOR HTS, SECTOR PR and 4-SPOT (DESIGN) are trademarks and/or service marks of Meso Scale Diagnostics, LLC. BD and Vacutainer are trademarks of Becton Dickinson & Co.

© 2010 Meso Scale Diagnostics, LLC. All rights reserved.

Table of Contents

table of contents

I.	Introduction	4
II.	Principle of the Assay	5
	Reagents Supplied	
IV.	Required Material and Equipment – not supplied	6
V.	Safety	7
VI.	Reagent Preparation	7
	Assay Protocol	
VIII.	Analysis of Results	9
IX.	Typical Standard Curve	10
Χ.	Sensitivity	10
XI.	Spike Recovery	11
XII.	Linearity	11
XIII.	Cross-Reactivity	12
XIV.	Assay Components	12
XV.	References	13
	Summary Protocol	15
	Plate Diagrams	17

Ordering Information

ordering information

MSD Customer Service

Phone: 1-301-947-2085 Fax: 1-301-990-2776

Email: CustomerService@mesoscale.com

MSD Scientific Support

Phone: 1-301-947-2025

Fax: 1-240-632-2219 attn: Scientific Support Email: ScientificSupport@mesoscale.com



Glucagon-like peptide-1 (GLP-1), a post-translational product of preproglucagon, is a 3.5 kD protein hormone produced in intestinal L cells and plays a key role in the promotion of glucose-dependent insulin secretion and insulin biosynthesis. In addition, GLP-1 works in concert with insulin to inhibit glucose secretion and thus lower overall blood glucose levels. Through the activation of different physiological systems, it plays roles in gastric emptying upon nutrient intake and in the regulation of short-term feeding behavior. Upon release, its action is mediated through a single G-protein-coupled receptor. GLP-1 receptors have been identified in several tissues, including pancreatic islets, lung, gastrointestinal tract and the central nervous system (CNS). Emerging evidence suggests GLP-1 also can provide beneficial, cyto-protective effects on neuronal cells, skeletal muscle and the myocardium, elevating its potential role in Alzheimer's and cardiovascular homeostasis and disease.

The cleaved peptides, commonly referred to as GLP-1 (7-36) amide and GLP-1 (7-37) are the biologically active forms of GLP-1. *In vivo*, these active isoforms are rapidly cleaved by dipeptidyl peptidase IV (DPP IV). Since GLP-1, in its bioactive form, plays a crucial role in blood glucose regulation, GLP-1 mimetics and inhibitors of DPP IV are currently being evaluated as potential drug candidates in treatment of diabetes. The primary amino acid sequence for GLP-1 is conserved among mammalian species, i.e. human, mouse, rat, monkey, canine, etc.

MSD offers a comprehensive array of GLP-1 assays that measure active, total and amidated isoforms of the GLP-1 protein using detection antibodies specific for the C-terminal amino acids.

Principle of the Assay

principle of the assay

MSD® metabolic assays provide rapid and convenient methods for measuring the levels of protein targets within single small-volume samples. The assays are available in both singleplex and multiplex formats. In a singleplex assay, an antibody for a specific protein target is coated on one electrode (or "spot") per well. In a multiplex assay, an array of capture antibodies against different targets is patterned on distinct spots in the same well. Our Human Total Active GLP-1 Assay detects GLP-1 (7-36) amide and GLP-1 (7-37) in a sandwich immunoassay (Figure 1). MSD provides a plate that has been pre-coated with Active GLP-1 capture antibody. The user adds the sample and a solution containing the labeled detection antibody—anti-GLP-1 (7-36) amide and anti-GLP-1 (7-37) labeled with an electrochemiluminescent compound, MSD SULFO-TAG™ label—over the course of one or more incubation periods. GLP-1 in the sample binds to capture antibody immobilized on the working electrode surface; recruitment of the labeled detection antibody by bound analyte completes the sandwich. The user adds an MSD read buffer that provides the appropriate chemical environment for electrochemiluminescence and loads the plate into an MSD SECTOR instrument for analysis. Inside the SECTOR instrument, a voltage applied to the plate electrodes causes the labels bound to the electrode surface to emit light. The instrument measures intensity of emitted light to afford a quantitative measure of GLP-1 (7-36) amide and GLP-1 (7-37) present in the sample (Figure 2).




Figure 1. Sandwich immunoassay on MSD platform. The numbering convention for the different spots is maintained in the software visualization tools, on the plate packaging, and in the data files. Any spot that is not coated with a specific capture antibody is blocked with BSA to reduce non-specific binding to that spot. A unique bar code label on each plate allows complete traceability back to MSD manufacturing records.



Figure 2. Schematic of the antibody recognition sites for the Total Active GLP-1 Assay on GLP-1 protein amino acids 1-37.

Reagents Supplied

ſ	9	a	9	ţ	S	(3 1		p	İ	9	d	

			Quantity per k	(it
Product Description	Storage	K151HZC-1	K151HZC-2	K151HZC-3
MULTI-SPOT 96-well Active GLP-1 Plate(s) N450ICA-1	2-8°C	1 plate	5 plates	20 plates
SULFO-TAG Anti-GLP-1 (7-36) amide Antibody ¹ (100X)	2-8°C	1 vial (40 µL)	1 vial (200 µL)	4 vials (200 μL ea)
SULFO-TAG Anti-GLP-1 (7-37) Antibody ¹ (100X)	2-8°C	1 vial (40 µL)	1 vial (200 µL)	4 vials (200 μL ea)
GLP-1 (7-36) amide Calibrator	<u><</u> -70°C	1 vial (15 µL)	5 vials (15 μL ea)	20 vials (15 µL ea)
Blocker A Kit R93AA-2 (250 mL)	RT	1 bottle (250 mL)	1 bottle (250 mL)	4 bottles (250 mL ea)
Aprotinin (200,000 KIU/mL)	2-8°C	1 vial (50 μL)	1 vial (250 µL)	4 vials (250 μL ea)
Blocker D-B (10%)	<u><</u> -10°C	1 vial (0.25 mL)	1 vial (1.2 mL)	4 vials (1.2 mL ea)
Blocker D-R (10%)	<u><</u> -10°C	1 vial (0.2 mL)	1 vial (1.0 mL)	4 vials (1.0 mL ea)
Blocker E (100X)	<u><</u> -10°C	1 vial (0.09 mL)	1 vial (0.45 mL)	4 vials (0.45 mL ea)
Diluent 6 R53BB-4 (8 mL) R53BB-3 (40 mL) R53BB-2 (200 mL)	<u><</u> -10°C	1 bottle (8 mL)	1 bottle (40 mL)	1 bottle (200 mL)
Diluent 12 R50JA-4 (10 mL) R50JA-3 (50 mL)	<u><</u> -10°C	1 bottle (10 mL)	1 bottle (50 mL)	2 bottles (50 mL ea)
Read Buffer T (4X) R92TC-3 (50 mL) R92TC-2 (200 mL)	RT	1 bottle (50 mL)	1 bottle (50 mL)	1 bottle (200 mL)

Required Materials and Equipment - not supplied

required materials and equipment — not supplied

■ Deionized water for diluting concentrated buffers

- 50 mL tubes for reagent preparation
- 15 mL tubes for reagent preparation
- Microcentrifuge tubes for preparing serial dilutions
- Phosphate buffered saline plus 0.05% Tween-20 (PBS-T) for plate washing
- Appropriate liquid handling equipment for desired throughput, capable of dispensing 10 to 150 μL into a 96-well microtiter plate
- Plate washing equipment: automated plate washer or multichannel pipette
- Adhesive plate seals
- Microtiter plate shaker

¹ Some SULFO-TAG labeled detection antibodies may be light-sensitive, so they should be stored in the dark.

Safety safet

Safe laboratory practices and personal protective equipment such as gloves, safety glasses, and lab coats should be used at all times during the handling of all kit components. All hazardous samples should be handled and disposed of properly, in accordance with local, state, and federal guidelines.

Reagent Preparation

reagent preparation

Bring all reagents to room temperature and thaw the Calibrator stock on ice.

Blockers D-B, D-R and E can tolerate up to 5 freeze-thaw cycles. Alternatively, an aliquot of each blocker can be stored at 2-8°C for up to 1 month.

Important: Upon first thaw, separate Diluent 6 and Diluent 12 into aliquots appropriate to the size of your assay needs. These diluents can go through up to three freeze-thaw cycles without significantly affecting the performance of the assay.

Prepare Blocker A Solution

Follow instructions included with the Blocker A Kit.

Prepare Metabolic Assay Working Solution

In a 15 mL tube combine (per plate):

- \Box 35 µL of Aprotinin
- □ 70 µL of Blocker E
- □ 6895 µL of Diluent 6

Important: Aprotinin should be added prior to use. The Metabolic Assay Working Solution should be kept on ice. Do not freeze the Metabolic Assay Working Solution for later use.

Prepare Calibrator and Control Solutions

Calibrator for the Total Active GLP-1 Assay is supplied at 1 μ g/mL. For the assay, an 8-point standard curve is recommended with 4-fold serial dilution steps and a zero Calibrator. The table below shows the concentrations of the 8-point standard curve:

Standard	GLP-1 (7-36) amide conc. (pg/mL)	Dilution Factor
Stock Cal. Vial	1000000	
STD-01	10000	100
STD-02	2500	4
STD-03	625	4
STD-04	156	4
STD-05	39	4
STD-06	9.8	4
STD-07	2.4	4
STD-08	0	n/a

To prepare this 8-point standard curve:

- 1) Prepare the highest Calibrator by transferring 10 μ L of the Calibrator stock solution at 1 μ g/mL to 990 μ L of Metabolic Assay Working Solution.
- 2) Prepare the next Calibrator by transferring 75 μ L of the diluted Calibrator to 225 μ L of Metabolic Assay Working Solution. Repeat 4-fold serial dilutions 5 additional times to generate 7 Calibrators.
- 3) The recommended 8th Standard is Metabolic Assay Working Solution (i.e. zero Calibrator).
- 4) Diluted Calibrators should be kept on ice prior to addition to the plate.

Note: The standard curve can be modified as necessary to meet specific assay requirements.

Preparation of Serum and Plasma Samples

The assay format requires 25 µL of sample per well. An adequate volume of each sample should be prepared depending upon desired number of replicates.

- a) Samples can be collected using BD™ P800 Blood Collection and Preservation System which contains DPP-IV and other protease inhibitor cocktails (Product Number 366420). Alternatively, whole blood should be collected into a lavender top BD Vacutainer® EDTA-plasma tube (Product Number 367841). DPP-IV inhibitor and Aprotinin should be added immediately to avoid cleavage/degradation of GLP-1. Spin the tubes for 10 minutes at 1000 x g (4°C).
- b) Samples can be stored at 2-8°C if used within 3 hours. Samples for later use should immediately be aliquotted into separate tubes and stored at ≤-70°C. Avoid repeated freeze-thaw (> 2) of these aliquots.
- c) Keep isolated or thawed samples on ice or at 4°C prior to subsequent processing or until use in the assay.
- d) Samples with hemolysis or significant lipemia may hinder accurate assay measurements.

Prepare Detection Antibody Solution

The Detection Antibodies are provided as 100X stock solutions. The working Solution should contain 1X as final concentration for each Detection Antibody.

For each plate used, combine:

30 μL of SULFO-TAG Anti-GLP-1 (7-36) amide Antibody
30 μL of SULFO-TAG Anti-GLP-1 (7-37) Antibody
90 μL of Blocker D-B
90 μL of Blocker D-R
2760 μL of Diluent 12

Prepare Read Buffer

The Read Buffer should be diluted 4-fold in deionized water to make a final concentration of 1X Read Buffer T. Add 5 mL of 4X Read Buffer T to 15 mL of deionized water for each plate.

Prepare MSD Plate

This plate has been pre-coated with antibody for the analyte shown in Figure 1. The plate can be used as delivered; no additional preparation (e.g., pre-wetting) is required. The plate has also been exposed to a proprietary stabilizing treatment to ensure the integrity and stability of the immobilized antibodies.

VII Assay Protocol

assay protocol

- 1. **Addition of Blocker A Solution:** Dispense 150 μL of Blocker A Solution into each well. Seal the plate with an adhesive plate seal and incubate for 1 hour with vigorous shaking (300–1000 rpm) at room temperature.
- 2. Wash and Addition of Sample or Calibrator: Wash the plate 3 times with PBS-T. Dispense 25 μL of Metabolic Assay Working Solution into each well of the MSD plate. Immediately add 25 μL of sample or Calibrator into the appropriate wells of the MSD plate. Seal the plate with an adhesive plate seal and incubate for 2 hours with vigorous shaking (300–1000 rpm) at room temperature.
- 3. Wash and Addition of the Detection Antibody Solution: Wash the plate 3 times with PBS-T. Dispense 25 μL of the 1X Detection Antibody Solution into each well of the MSD plate. Seal the plate and incubate for 1 hour with vigorous shaking (300–1000 rpm) at room temperature.
- 4. Wash and Read: Wash the plate 3 times with PBS-T. Add 150 μL of 1X Read Buffer T to each well of the MSD plate. Analyze the plate on the SECTOR Imager. Plates may be read immediately after the addition of Read Buffer.

Notes

Shaking a 96-well MSD MULTI-SPOT plate typically accelerates capture at the working electrode.

Bubbles in the fluid will interfere with reliable reading of MULTI-SPOT plate. Use reverse pipetting techniques to insure bubbles are not created when dispensing the Read Buffer.




analysis of results

The Calibrators should be run in duplicate to generate a standard curve. The standard curve is modeled using least squares fitting algorithms so that signals from samples with known levels of the analyte of interest can be used to calculate the concentration of analyte in the sample. The assays have a wide dynamic range (3–4 logs) which allows accurate quantification in many samples without the need for dilution. The MSD DISCOVERY WORKBENCH® analysis software utilizes a 4-parameter logistic model (or sigmoidal dose-response) and includes a 1/Y² weighting function. The weighting functionality is important because it provides a better fit of data over a wide dynamic range, particularly at the low end of the standard curve.

Typical Standard Curve

The MSD Human Total Active GLP-1 Assay is designed for use with human serum and plasma samples.

The following standard curve is an example of the dynamic range of the assay. The actual signals may vary. A standard curve should be run for each set of samples and on each plate for the best quantification of unknown samples.



	Total Active C	LP-1
Conc. (pg/mL)	Average Signal	%CV
0	141	4.4
2.4	259	7.8
9.8	614	4.4
39	2897	11.9
156	20832	3.3
625	134799	9.2
2500	626726	2.3
10000	1221331	6.5

X Sensitivity

The lower limit of detection (LLOD) is the calculated concentration of the signal that is 2.5 standard deviations over the zero Calibrator. The value below represents the average LLOD over multiple kit lots.

1 pmol/L = 3.297 pg/mL

	Total Active GLP-1
LLOD (pg/mL)	1.3

Spike Recovery

Serum, EDTA plasma, and heparin plasma were spiked with the Calibrators at multiple values throughout the range of the assay. Measured analyte represents average spike recovery in 4-6 pooled human serum and plasma samples. MSD recommends using plasma samples for optimal assay performance.

% Recovery = measured /expected x 100

_	Spike Conc. (pg/mL)	% Recovery
	100	73
Spiked Serum	500	83
	1000	84
	100	100
Spiked EDTA Plasma	500	119
	1000	131
	100	84
Spiked Heparin Plasma	500	91
	1000	106



Linearity was measured by spiking Calibrator levels in pooled human plasma followed by subsequent dilution.

Percent recovery is calculated as the measured concentration divided by the concentration of the previous dilution (expected).

% Recovery = measured x dilution factor / expected x 100

	Fold Dilution	% Recovery
	2	105
Serum	4	111
	8	81
	2	96
EDTA Plasma	4	91
	8	65
	2	106
Heparin Plasma	4	107
	8	70



The cross-reactivity shown below is calculated based on signal generated using different GLP-1 isoforms.

Total Active GLP-1				
Form	Cross-Reactivity			
GLP-1 (7-36) amide	100%			
GLP-1 (9-36) amide	< 0.1%			
GLP-1 (1-36) amide	< 0.1%			
GLP-1 (7-37)	31%			
GLP-1 (1-37)	< 0.1%			



XIV Assay Components

assay components

Calibrator					
Analyte	GLP-1 (7-36) amide				
Source	Synthetic amidated peptide (amino acids 7-36) of human GLP-1				

Capture Antibody					
Analyte	Active GLP-1				
Source	Mouse monoclonal				
Isoforms Recognized	Reacts with GLP-1 (7-36) amide and GLP-1 (7-37), does not				
isolomis Recognized	react with GLP-1 (9-36) or GLP-1 (9-37)				
Species cross-reactivity	Human, mouse, rat (100% conserved in all mammalian species)				

Detection Antibody 1	
Analyte	GLP-1
Source	Mouse monoclonal
Isoforms Recognized	Reacts with the amidated C terminus of GLP-1 (7-36) amide, GLP-1 (9-36) amide and GLP-1 (1-36) amide, does not react with GLP-1 (7-37), GLP-1 (9-37) or GLP-1 (1-37)
Species cross-reactivity	Human, mouse, rat (100% conserved in all mammalian species)

Detection Antibody 2	
Analyte	GLP-1
Source	Rabbit polyclonal
Isoforms Recognized	Reacts with GLP-1 (7-37), GLP-1 (1-37) and GLP-1 (9-37),
	limited activity to GLP-1 (1-36) amide
Species cross-reactivity	Human, mouse, rat (100% conserved in all mammalian species)

XV References

references

- 1. Kieffer TJ, Habener JF. The Glucagon-Like Peptides. Endo Reviews. 2006 Dec;20(6):876-913
- 2. Pospisilik JA, Martin J, Doty T, et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes. 2003 Mar;52(3):741-50.
- 3. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007 May;132(6):2131-57.
- 4. Holst JJ, Deacon CF. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr Opin Pharmacol. 2004 Dec;4(6):589-96
- Deacon CF, Johnsen AH, Holst JJ. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an Nterminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995 Mar;80(3):952-7

Summary Protocol

MSD 96-well MULTI-ARRAY Human Total Active GLP-1 Assay Kit

MSD provides this summary protocol for your convenience. Please read the entire detailed protocol prior to performing the Human Total Active GLP-1 Assay.

Step 1: Sample and Reagent Preparation

Bring all reagents to room temperature and thaw the Calibrator stock on ice.

Prepare Blocker A Solution.

Prepare serum or plasma samples.

Prepare Metabolic Assay Working Solution and keep on ice.

Prepare an 8-point standard curve using supplied Calibrator:

- The Calibrator should be diluted in Metabolic Assay Working Solution.
- Dilute the stock Calibrator 1:100 as indicated in Reagent Preparation section, then perform a series of 4-fold dilution steps and a no Calibrator blank.
- Diluted Calibrators should be kept on ice until use.

Note: The standard curve can be modified as necessary to meet specific assay requirements.

Prepare Detection Antibody Solution as indicated in Reagent Preparation section.

Prepare 20 mL of 1X Read Buffer T by diluting 4X Read Buffer T with deionized water.

Step 2: Add Blocker A Solution

Dispense 150 µL/well Blocker A Solution.

Incubate at room temperature with vigorous shaking (300–1000 rpm) for 1 hour.

Step 3: Wash and Add Sample or Calibrator

Wash plate 3 times with PBS-T.

Dispense 25 µL/well Metabolic Assay Working Solution.

Immediately, dispense 25 µL/well Calibrator or Sample.

Incubate at room temperature with vigorous shaking (300–1000 rpm) for 2 hours.

Step 4: Wash and Add Detection Antibody Solution

Wash plate 3 times with PBS-T.

Dispense 25 µL/well 1X Detection Antibody Solution.

Incubate at room temperature with vigorous shaking (300–1000 rpm) for 1 hour.

Step 5: Wash and Read Plate

Wash plate 3 times with PBS-T.

Dispense 150 µL/well 1X Read Buffer T.

Analyze plate on SECTOR instrument.

